Tohru Ohmori

Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo.

Phase I study of the combination of gemcitabine and nedaplatin for treatment of previously untreated advanced non-small cell lung cancer.

Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer.

Patients preferences in chemotherapy for advanced non-small-cell lung cancer.

The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer.

Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib.

Phase II study of the combination of gemcitabine and nedaplatin for advanced non-small-cell lung cancer.

Phase II study of biweekly administration of docetaxel and irinotecan in patients with refractory or relapsed advanced non-small cell lung cancer.

Phase I study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer.

Mutant epidermal growth factor receptor undergoes less protein degradation due to diminished binding to c-Cbl.

Effectiveness of intensive follow-up after response in patients with small cell lung cancer.

Patient willingness to undergo chemotherapy and thoracic radiotherapy for locally advanced non-small cell lung cancer.

Phase II study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer.

Combination effect between bortezomib and tumor necrosis factor alpha on gefitinib-resistant non-small cell lung cancer cell lines.

Induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer.

EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma.

[Chemotherapy-induced myelosuppression and treatment efficacy in limited-stage disease small cell lung cancer].

The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer.

Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?

Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer.

Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.

Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer.

[The mechanisms of resistance to EGFR-TKIs and challenges to overcome resistance in EGFR mutant non-small cell lung cancer].

MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.

Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer.

Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease.

Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer.

Prognostic impact of the number of viable circulating cells with high telomerase activity in gastric cancer patients: a prospective study.

Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.

Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.

Long-term prognostic impact of circulating tumour cells in gastric cancer patients.

Change in number and size of circulating tumor cells with high telomerase activity during treatment of patients with gastric cancer.

Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.

and Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in .

Receptor Tyrosine Kinase-Targeted Cancer Therapy.